Sign Up | Log In | What is SocialPicks?

Biogen Idec Inc (BIIB) Trade Now » Rate BIIB - Discuss BIIB - Add to Watch List

Sector: Healthcare > Industry: Biotechnology & Drugs

SocialPicks Sentiment:

** v.s. other stocks

This Quarter's Sentiment:

All:

80.0%

Top:

66.5%

Rate BIIB:

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

BIIB: Bull or Bear?

From: SocialPicks | Blogsphere | All

SocialPicks Community

Bullish on BIIB ... BIIB

74%

ROE should begin to rise...great P/E ratio as well

Continue reading »

By Marc M (+4.67% risk: aggressive) 07/11/07

Comment

Mojo Crossover.....Buy and Sell Points (BIIB) BIIB

60%

Mojo Crossover »»» Bullish Takeover Speculation <> !
<>

<> <>
(BIIB) Biogen Idec Inc. ( Google Yahoo Earnings Chart Barchart ) <>

Biogen Idec Inc., is involved in the development, manufacturing and commercialization of therapies in the areas of oncology, neurology and immunology. The Company has five products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab), ZEVALIN (ibritumomab tiuxetan) and FUMADERM (dimethylfumarate and monoethylfumarate salts). In Nov...

Continue reading »

By Bob (+0.54% risk: aggressive) 05/28/07

Comment

ROCK-STAR INVESTORS

Rank	Name	Sharpe Ratio	Avg Return	Followers
1	noshoes	21.10	+34.44%	381
2	Gerald Greene	18.14	+71.24%	211
3	stockmarketfunding.com	17.66	+25.60%	55
4	akiralegrand	13.47	+14.32%	62
5	anup2104	12.13	+74.22%	40

... more »

POPULAR STOCKS

Symbol	Company Name	Sentiment
DELL	Dell Inc
BA	The Boeing Company
MSFT	Microsoft Corp
RIO	Companhia Vale Do Rio Doce
AMZN	Amazoncom Inc
KO	The CocaCola Company

... more »

TODAY'S HEADLINES

LDK Solar's Growth Potential Offset by Gross Margin Pressure
by Paul Cheung (Zacks.com) about LDK

Cisco Systems Still a Wait and See
by Thomas Catino (Ant & Sons) about CSCO

The Merrill Lynch Diet: Starving Shareholders
by Zack Miller (BloggingStocks) about MER

Until Housing Improves, Don't Expect Stocks to Rebound
by J.D. Steinhilber (Agile Investing) about SPY

Google Blows Q2: Multiple Compression to Continue
by Henry Blodget about GOOG

... more »

TODAY'S TOP PICKS

DNDN		Cancer Vaccines: Investing Opportunities beyond Dendreon (NASDAQ: D... by Mike Havrilla
CLDA		BioMed Research Reports: Clinical Data (NASDAQ: CLDA), Lpath (OTC: ... by Mike Havrilla
PARD		Biotech Stocks - Beware of The Covered Call Trap by Ivan Mutaftchiev
PBIO		Under the Radar Healthcare Stocks: Protox, Pressure BioSciences, Un... by Mike Havrilla
ISIS		ISIS - Last Tuesday's Drop Presents a Nice Buy Opportunity by Ivan Mutaftchiev

... more »

StreetInsider.com on BIIB

Visit streetinsider.com

Discussion Wall

+ Add

amritadas (+0.00%)

A FREE report on the approval of a new Gout Drug - FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by th...

+	0 replies

amritadas (+0.00%)

Free report on upcoming FDA panel decision of Corvu.. - FDA Panel to review this Biotech company's stress agent drug on July 28th. If they get a favorable backing by the panel, the chances of approval by th...

+	0 replies

... more »

More Resources

About Biogen Idec Inc - Answers.com

Historical Prices - Yahoo

Message Boards - BoardCentral.com

More Info: Yahoo | Google | Reuters

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.